virica™

The Solution to Cost & Yield Challenges in Vaccine Manufacturing

Case Study: As little as 50% increase in yields with VSEs leads to significant savings

Current Process Costly, Inefficient	**VSE Enhanced Process** Optimized, Efficient
High manufacturing costs **($8.39/dose)**	**33% decrease** in costs **($5.60/dose)**
Low yields **limiting vaccine supply**	**50% increase** in viral yields
Excess plastic waste **(124kg)**	Reduces manufacturing waste **(83kg)**

Source: *BioSolve Process Modeling Case Study*

How VSEs™ Optimize Vaccine Manufacturing

- Maximizes viral yields across substrates and cell lines (**up to 10x increase***)
- Reduces vaccine production costs (Up to **57% per dose**)
- Enhance sustainability (**56% less plastic waste**)

What Are VSEs™?

Small molecules that boost upstream viral yield and quality by dampening innate cellular defenses in producer cells.

**Yield enhancement depends on application*

Case Study: *Yield vs. Cost Reduction in Upstream Vaccine Production*



- 1.5x Yield = 33% Cost Reduction ($5.60/dose)
- 2x Yield = 46% Cost Reduction ($4.54/dose)
- 3x Yield = 57% Cost Reduction ($3.65/dose)

What's Next? Integrating VSEs™ into Vaccine Production

Ready to scale production and cut costs without disrupting your current workflow? Experience:

Seamless Integration:

VSEs™ are upstream additives easily implemented into manufacturing platforms without disruption

Immediate Impact:

Increase yields, lower costs, and enhance sustainability with minimal adjustments

Proven Results:

Join leading biotech companies already optimizing their upstream bioprocessing with VSE™

Speak with an Expert